A gastrointestinal oncologist told Newsweek that the early-stage findings are a “major step forward” in targeting colon ...
Loss of GATA6-a transcription factor that controls which genes are turned on or off-can reprogram colorectal cancer cells ...
Loss of GATA6—a transcription factor that controls which genes are turned on or off—can reprogram colorectal cancer cells ...
A newly identified loss of cellular identity may enable colorectal cancer cells to enter a highly flexible state that promotes liver metastasis.
Zanzalintinib plus atezolizumab showed significant survival benefits over regorafenib in non-MSI-high metastatic colorectal cancer patients in the STELLAR-303 trial. The trial's safety profile was ...
Researchers at the Medical University of Vienna have described a mechanism in metastatic colorectal cancer that has received ...
Combining PDS01ADC with HAIP FUDR achieved a 77.8% 6-month ORR in nine mCRC liver-metastasis patients, compared with ~35% reported in a parallel HAIP-only experience. Two-year overall survival was ~85 ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved encorafenib plus cetuximab and fluorouracil-based chemotherapy for adults with BRAF ...
mCRC treatment involves balancing efficacy, tolerability, and patient goals, with fruquintinib, regorafenib, and trifluridine-tipiracil as key therapies. Oncology pharmacists are essential in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results